Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02970019 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease
A Phase 1 study of Parkinson Disease, sponsored by Sun Pharma Advanced Research Company Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 5
- Study locations
NCT02970019 is a Phase 1 study of Parkinson Disease that has completed, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 60 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT02970019, a Phase 1 study of Parkinson Disease, has completed, sponsored by Sun Pharma Advanced Research Company Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a safety, tolerability and pharmacokinetic study in subjects with Parkinson's disease
Conditions Studied
Interventions
- DRUG Placebo
- DRUG K0706
Study Locations (5)
California
- SPARC Site 03 - Long Beach
- SPARC Site 05 - Panorama City
Florida
- SPARC Site 01 - DeLand
- SPARC Site 02 - Orlando
North Carolina
- SPARC Site 04 - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-03-30 |
| Est. Completion | 2019-05-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02970019
The ClinicalTrials.gov registry entry for NCT02970019 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The listed sponsor is Sun Pharma Advanced Research Company Limited, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02970019 reports 5 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02970019 about?
NCT02970019 is a clinical study titled "Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease". This is a safety, tolerability and pharmacokinetic study in subjects with Parkinson's disease
What is the current status of trial NCT02970019?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2017-03-30. Estimated completion is 2019-05-28.
What conditions does trial NCT02970019 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT02970019?
The interventions under investigation include: Placebo (DRUG), K0706 (DRUG).
Who is sponsoring clinical trial NCT02970019?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02970019 being conducted?
This trial has 5 study locations across California, Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
RECRUITING · Phase 1
-
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
RECRUITING · Phase 1
-
First-in-Human Single and Multiple Dose of HL-400
RECRUITING · Phase 1
-
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
RECRUITING · Phase 1
-
[18F]F-DOPA Imaging in Patients With Autonomic Failure
RECRUITING · Phase 1
-
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.